Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ120212030,00
KB10031005-0,59
PKN73,9673,980,33
Msft469,93470,28-0,03
Nokia4,7414,746-0,50
IBM268,7269,5-0,04
Mercedes-Benz Group AG51,5951,610,49
PFE23,4523,460,47
09.06.2025 11:38:00
Indexy online
AD Index online
select
AD Index online
 

  • 06.06.2025
Amicus Therap (NASDAQ Cons)
Závěr k 6.6.2025 Změna (%) Změna (USD) Objem obchodů (ks)
6,16 3,36 0,20 5 145 581
Premarket09.06.2025 11:19:50
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 6,14 6,32 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.06.2025
Popis společnosti
Obecné informace
Název společnostiAmicus Therapeutics, Inc.
TickerFOLD
Kmenové akcie:Ordinary Shares
RICFOLD.O
ISIN-
Prioritní akcieConv. Pref. Shrs Series A
Prioritní akcieConv. Pref. Shrs Series B
Prioritní akcieConv. Pref. Shrs Series C
Prioritní akciePreference Shares Series D
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 499
Akcie v oběhu k 24.04.2025 307 930 984
MěnaUSD
Kontaktní informace
Ulice47 Hulfish Street
MěstoPRINCETON
PSČ08542
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 096 622 000
Fax16096622001

Business Summary: Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Amicus Therapeutics, Inc. revenues increased 13% to $125.2M. Net loss decreased 55% to $21.7M. Revenues reflect U.S segment increase of 34% to $50M, Ex U.S segment increase of 3% to $75.3M. Lower net loss reflects Restructuring charges decrease from $6M (expense) to $0K, Other income (expense) increase from $5M (expense) to $550K (income).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 09.06.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorBradley Campbell4901.08.2022
Chief Financial OfficerSimon Harford6421.08.202321.08.2023
Chief People OfficerDavid Clark50
Chief Development OfficerJeffrey Castelli53
Chief Legal Officer, Corporate SecretaryEllen Rosenberg6208.02.2016